Member Info for VertizeaSun

Tomorrow might be a bit of a push but the following eight working days is nailed on, with the AGM and the quarterly update due by a week Monday. And if the management don't take this opportunity to talk-up Phase 1B they will richly deserve the heavy duty Anglo-Saxon expletives likely to be coming their way.

Don't make eye contact.

Thanks but firewalled. Please copy & paste.

Cranmer and Tap know it work's....from last week's RNS:
"The US trial sites will initially contribute patients to the dose escalation phase, while being uniquely positioned to lead the enrolment of soft tissue sarcoma patients in the phase 1b dose expansion stage of the AVA6000 study when this begins."

Good Lord! And on a Saturday morning too!

AS's February letter to the Times more or less told us he's considering moving to NASDAQ and for it to be a useful defence against Big Pharma requires implementation before the end of September. Anyone planning a TO in 2024 is already an also-ran.

"Could Avacta be negotiating to licence AVA2727D to Takeda??"

AS told them the price and their board retired to a darkened room to lie down.

Investor Presentation 25 April 2023:

Besides the obvious pre|CISION AVA updates and a briefing on FDA Fast Track development I’d also like to hear about:

1: AffyXell Therapeutics and Daewoong Pharmaceutical Co. Ltd.

2: LG Chem and Affimer® therapeutics.

3: Progress on the next generation Affimer based sepsis LFT.

Of course I’d also like the CEO to talk about potential licensing deals and further Diagnostic acquisitions but that's probably not likely at the moment.

All true and that makes POINT Biopharma's commitment in Jan 21 all the more interesting. And they are really running with pre|Cision.....(CanSEEK)

ditto

Is Hurstbot linking to ChatGPT?

5 (words) is the sum of your intelligence.

"@MylesMcNulty
·
19h
I noted some debate on Twitter over the weekend about the current probability of #AVCT's #AVA6000 making it to market.

I would suggest that the true value of
@avacta
is NOT in 6K, nor even in #AVA3996.

The value is in the global exclusive license of this patent family... 8/13"

In his 13 Tweet thread MM points out that pre|CISION itself is now absolutely proven, as a delivery mechanism, and consequently is priceless. AVA6K is only a tiny part of the picture.

https://twitter.com/MylesMcNulty/status/1647941373700579329

Because NASDAQ is 90 times more liquid than AIM. AS is in the wrong place and his letter to the Times proves he knows it. I fully expect him to resolve it.

Timster:
I agree but my point is that wynbores all seeing/all knowing "market' values the IP and patents at the commercial equivalent of a stick of gum. Unless AS moves to protect his backside this company will be sold for 4 quid a share. Does he have the luxury of waiting until 2024? I think not.

I think we'll know about AS's Plan A long before Phase 1B. My money is on next Tuesday.

What bloody "market" ..... a few dozen dime-a-day traders! Low liquidity is no surprise when our own advisers "award' us 20% COS.
GET ONTO NASDAQ and away from this children's game.

Pharma is too late. The FDA know about it,,,,,ODD remember.

Alextak....1 comment left by Jean-Pierre Lacaze :

And the Dox works too. It's ludicrous to think Dr William Tap and his colleague would enrol 60+ patients if it didn't. That would be criminal malpractice.

Touk....exactly.
The AIM market simply doesn't have enough liquidity and that means a few hundred dime-a-day traders run Avacta's SP. I actually think the AIM market is worthwhile, and has its place in the grand scheme of things, but it's too small for Avacta.
Numbers I dug up a couple of months ago show NASDAQ capitalised at $13 Trillion, compared to the entire LSE at about £3.5 Trillion. Little AIM comes in with a capitalisation of £142 Billion.
This makes NASDAQ more than 90 times bigger than AIM. That extra liquidity would turbo charge Avacta's SP and probably allow AS to stay independent.
Here's hoping that AS's letter to the Times was a head's up......fingers crossed!